



Article scientifique

Article

2023

Erratum

Open Access

This file is a(n) Erratum of:

EULAR recommendations for the management of rheumatoid arthritis with
synthetic and biological disease-modifying antirheumatic drugs: 2022
update

Smolen, Josef S; Landewé, Robert B M; Bergstra, Sytske Anne; Kerschbaumer, Andreas;
Sepriano, Alexandre; Aletaha, Daniel; Caporali, Roberto; Edwards, Christopher John; Hyrich, Kimme L;
Pope, Janet E; de Souza, Savia; Stamm, Tanja A; Takeuchi, Tsutomu; Verschueren, Patrick [and 34
more]

This publication URL: <https://archive-ouverte.unige.ch/unige:169382>

Publication DOI: [10.1136/ard-2022-223356](https://doi.org/10.1136/ard-2022-223356)

Correction: *EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update*

Smolen JS, Landewé RBM, Bergstra SA, *et al.* EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. *Ann Rheum Dis* 2023;82:3–18.

The competing interests statement was erroneously omitted and is now included. This correction has not been made in print.

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Ann Rheum Dis 2023;82:e76. doi:10.1136/ard-2022-223356corr1

